Similar evidence was found in a phase II study that combined Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4), obtaining an improvement of overall survival in patients with advanced refractory CRC [120]. This evidence concerns the gene CD274 and colorectal carcinoma.